Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility

Overview

Journal Int J Gynecol Pathol

Specialties Gynecology & Obstetrics
Pathology

Date 2018 Mar 9

PMID 29517499

Citations 133

Authors

Martin Kobel

Brigitte M Ronnett

Naveena Singh

Robert A Soslow

C Blake Gilks

W Glenn McCluggage

Affiliations

Soon will be listed here.

Abstract

P53 immunohistochemistry has evolved into an accurate surrogate reflecting the underlying TP53 mutation status of a tumor, and has utility in the diagnostic workup of endometrial carcinomas. Recent work predominantly carried out in tubo-ovarian high-grade serous carcinoma has revealed 4 main patterns of p53 staining (normal/wild-type, complete absence, overexpression, and cytoplasmic); the latter 3 patterns are variably termed abnormal/aberrant/mutation-type and are strongly predictive of an underlying TP53 mutation. The aim of this review is to provide practical advice to pathologists regarding various aspects of p53 immunohistochemical staining. These include laboratory methods to optimize staining, a description of the different patterns of staining, advice regarding the interpretation, and reporting of p53 staining and practical uses of p53 staining in endometrial carcinoma diagnosis. Illustrations are provided to aid in the interpretational problems.

Citing Articles

The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.

Molefi T, Mabonga L, Hull R, Mwazha A, Sebitloane M, Dlamini Z Cells. 2025; 14(5).

PMID: 40072110 PMC: 11898822. DOI: 10.3390/cells14050382.

A Machine Learning Approach to Build and Evaluate a Molecular Prognostic Model for Endometrial Cancer Based on Tumour Microenvironment.

Wu D, Yan Z, Li M, Wang M, Meng Y J Cell Mol Med. 2025; 29(4):e70316.

PMID: 39981812 PMC: 11843467. DOI: 10.1111/jcmm.70316.

Evaluation of Grading Estrogen Receptors in Breast Cancer Using Fully Automated Rapid Immunohistochemistry Based on Alternating-Current Electric Field Technology.

Kudo C, Terata K, Nanjo H, Nomura K, Hiroshima Y, Takahashi E Cancers (Basel). 2025; 17(3).

PMID: 39941732 PMC: 11816054. DOI: 10.3390/cancers17030363.

Clinical and molecular analysis of JCPyV and BKPyV infection and associated risk of urothelial carcinoma development in the upper tract.

Chao C, Hung C, Lai W, Tung C, Yeh W, Yang K Virol J. 2025; 22(1):32.

PMID: 39923063 PMC: 11806556. DOI: 10.1186/s12985-025-02643-8.

DECODE enables high-throughput mapping of antibody epitopes at single amino acid resolution.

Matsumoto K, Harada S, Yoshida S, Narumi R, Mitani T, Yada S PLoS Biol. 2025; 23(1):e3002707.

PMID: 39847587 PMC: 11756784. DOI: 10.1371/journal.pbio.3002707.

References

Talhouk A, McConechy M, Leung S, Yang W, Lum A, Senz J . Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123(5):802-813. DOI: 10.1002/cncr.30496. View

Chen W, Husain A, Nelson G, Rambau P, Liu S, Lee C . Immunohistochemical Profiling of Endometrial Serous Carcinoma. Int J Gynecol Pathol. 2016; 36(2):128-139. DOI: 10.1097/PGP.0000000000000291. View

Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks M, Shih I . Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011; 24(9):1248-53. DOI: 10.1038/modpathol.2011.85. View

McCluggage W, Soslow R, Gilks C . Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance. Histopathology. 2011; 59(4):786-8. DOI: 10.1111/j.1365-2559.2011.03907.x. View

Kobel M, Piskorz A, Lee S, Lui S, Lepage C, Marass F . Optimized p53 immunohistochemistry is an accurate predictor of mutation in ovarian carcinoma. J Pathol Clin Res. 2016; 2(4):247-258. PMC: 5091634. DOI: 10.1002/cjp2.53. View

Casey L, Kobel M, Ganesan R, Tam S, Prasad R, Bohm S . A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. Histopathology. 2017; 71(5):736-742. DOI: 10.1111/his.13272. View

Stelloo E, Nout R, Osse E, Jurgenliemk-Schulz I, Jobsen J, Lutgens L . Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res. 2016; 22(16):4215-24. DOI: 10.1158/1078-0432.CCR-15-2878. View

Bosse T, Nout R, McAlpine J, McConechy M, Britton H, Hussein Y . Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. Am J Surg Pathol. 2018; 42(5):561-568. PMC: 5893364. DOI: 10.1097/PAS.0000000000001020. View

Fadare O, Gwin K, Desouki M, Crispens M, Jones 3rd H, Khabele D . The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol. 2013; 26(8):1101-10. PMC: 3886836. DOI: 10.1038/modpathol.2013.35. View

10.

Bakhsh S, Kinloch M, Hoang L, Soslow R, Kobel M, Lee C . Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. Histopathology. 2015; 68(6):916-24. PMC: 5650229. DOI: 10.1111/his.12878. View

11.

Nastic D, Shanwell E, Wallin K, Valla M, Masback A, Mateoiu C . A Selective Biomarker Panel Increases the Reproducibility and the Accuracy in Endometrial Biopsy Diagnosis. Int J Gynecol Pathol. 2017; 36(4):339-347. DOI: 10.1097/PGP.0000000000000334. View

12.

Torlakovic E, Nielsen S, Vyberg M, Taylor C . Getting controls under control: the time is now for immunohistochemistry. J Clin Pathol. 2015; 68(11):879-82. PMC: 4680144. DOI: 10.1136/jclinpath-2014-202705. View

13.

Kobel M, Reuss A, du Bois A, Kommoss S, Kommoss F, Gao D . The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 2010; 222(2):191-8. DOI: 10.1002/path.2744. View

14.

Kobel M, Meng B, Hoang L, Almadani N, Li X, Soslow R . Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases. Am J Surg Pathol. 2015; 40(2):166-180. PMC: 5029122. DOI: 10.1097/PAS.0000000000000536. View

15.

Karnezis A, Hoang L, Coatham M, Ravn S, Almadani N, Tessier-Cloutier B . Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod Pathol. 2016; 29(3):302-14. PMC: 4980656. DOI: 10.1038/modpathol.2015.155. View

16.

Hussein Y, Weigelt B, Levine D, Schoolmeester J, Dao L, Balzer B . Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2014; 28(4):505-14. DOI: 10.1038/modpathol.2014.143. View

17.

Altman A, Ferguson S, Atenafu E, Kobel M, McAlpine J, Panzarella T . Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. Gynecol Oncol. 2015; 139(2):268-74. DOI: 10.1016/j.ygyno.2015.09.001. View

18.

Schultheis A, Martelotto L, De Filippo M, Piscuglio S, Ng C, Hussein Y . TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. Int J Gynecol Pathol. 2015; 35(4):289-300. PMC: 5087968. DOI: 10.1097/PGP.0000000000000243. View

19.

Cole A, Dwight T, Gill A, Dickson K, Zhu Y, Clarkson A . Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci Rep. 2016; 6:26191. PMC: 4870633. DOI: 10.1038/srep26191. View

20.

Lehmann S, Bykov V, Ali D, Andren O, Cherif H, Tidefelt U . Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012; 30(29):3633-9. DOI: 10.1200/JCO.2011.40.7783. View